How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Branched Aortic Stent-Graft System Market
- By Device Type: Single-Branched Stent-Grafts, Double-Branched Stent-Grafts, Triple-Branched Stent-Grafts
- By Material Type: Nitinol Stent Frame, Stainless Steel Stent Frame, Polyester Fabric Graft, ePTFE Fabric Graft
- By Indication: Thoracic Aortic Aneurysm, Aortic Dissection, Aortic Arch Pathologies, Thoracoabdominal Aortic Aneurysm
- By End User: Hospitals, Specialty Vascular Clinics, Ambulatory Surgical Centers
- By Procedure Approach: Endovascular Repair, Hybrid Repair (Open + Endovascular)
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Single-Branched Stent-Grafts leads By Device Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 13 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 280 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.171 →
- 12 Company Profiles 13 players: SWOT & benchmarking p.179 →
Full report · locked preview
Everything inside the Branched Aortic Stent-Graft System Market report
A complete, evidence-based study - 12 chapters and 117 sections covering market size, segmentation across 5 axes, regional analysis and 13 company profiles, forecast to 2033.
Segmentation covered
Device Type 3
Material Type 4
Indication 4
End User 3
Procedure Approach 2
Companies profiled
Medtronic
W.L. Gore & Associates
Cook Medical
Terumo Corporation
Endologix (a subsidiary of Philips)
Jotec GmbH
Bolton Medical
MicroPort Scientific Corporation
Vascutek (Terumo Group)
Cardinal Health
Bard Peripheral Vascular (BD)
C.R. Bard (BD)
+1 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
13 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Medtronic
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →W.L. Gore & Associates
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Cook Medical
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Terumo Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Endologix (a subsidiary of Philips)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Jotec GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Bolton Medical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →MicroPort Scientific Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Vascutek (Terumo Group)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Cardinal Health
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Bard Peripheral Vascular (BD)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →C.R. Bard (BD)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Lombard Medical
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,798M by 2033 · 4.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Single-Branched Stent-Grafts61.4
- Double-Branched Stent-Grafts17.0
- Triple-Branched Stent-Grafts21.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,575M → $2,373M · 5.3%
Europe$1,098M → $1,615M · 4.9%
Asia Pacific$1,002M → $1,512M · 5.3%
Latin America$620.4M → $894.1M · 4.7%
Middle East and Africa$477.2M → $642.4M · 3.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.472026
4.482027
4.502028
4.502029
4.532030
4.532031
4.542032
4.562033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Medtronic17.5
- W.L. Gore & Associates24.1
- Cook Medical10.9
- Terumo Corporation11.8
- Endologix (a subsidiary of Philips)3.8
- Jotec GmbH4.0
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Device Type28.8%
Material Type14.0%
Indication22.1%
End User23.9%
Procedure Approach11.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.7
- Europe23.0
- Asia Pacific21.5
- Latin America12.7
- Middle East and Africa9.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Medtronic | 88 | 91 | 89 | 92 | 80 | 87 | 88 |
| W.L. Gore & Associates | 80 | 83 | 72 | 80 | 85 | 75 | 79 |
| Cook Medical | 86 | 74 | 78 | 80 | 66 | 64 | 75 |
| Terumo Corporation | 59 | 79 | 68 | 70 | 73 | 64 | 69 |
| Endologix (a subsidiary of Philips) | 61 | 66 | 70 | 66 | 65 | 68 | 66 |
| Jotec GmbH | 52 | 55 | 58 | 60 | 71 | 47 | 57 |
| Bolton Medical | 47 | 50 | 45 | 43 | 42 | 56 | 47 |
| MicroPort Scientific Corporation | 44 | 59 | 40 | 38 | 41 | 56 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Medtronic
- W.L. Gore & Associates
- Cook Medical
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Medtronic | ◐ | ✓ | ✓ | ✓ | ✓ | ◐ |
| W.L. Gore & Associates | ◐ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Cook Medical | ✓ | ✓ | ◐ | ✓ | ✓ | ✓ |
| Terumo Corporation | − | ◐ | ◐ | ◐ | ✓ | ◐ |
| Endologix (a subsidiary of Philips) | ◐ | ◐ | ✓ | − | − | ◐ |
| Jotec GmbH | ◐ | ◐ | − | ◐ | ✓ | ◐ |
| Bolton Medical | − | − | − | − | − | ◐ |
| MicroPort Scientific Corporation | − | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Medtronic88
2W.L. Gore & Associates79
3Cook Medical75
4Terumo Corporation69
5Endologix (a subsidiary of Philips)66
6Jotec GmbH57
7Bolton Medical47
8MicroPort Scientific Corporation46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
MedtronicW.L. Gore & Associates
Challenger2
Strong scale, closing on the leaders.
Cook MedicalTerumo Corporation
Contender2
Focused players with pockets of strength.
Endologix (a subsidiary of Philips)Jotec GmbH
Niche2
Specialists in a single segment or region.
Bolton MedicalMicroPort Scientific Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Device Type in North America, then scale across Branched Aortic Stent-Graft System Market — a $484M beachhead inside a $7.65B market.
Beachhead (SOM)$484Mobtainable near-term
Serviceable (SAM)$2.79Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
Single-Branched Stent-Grafts
Best fit — highest urgency & budget in Device Type.
Economic buyer75 fit
Double-Branched Stent-Grafts
Strong fit — clear ROI and a fast path to value.
End user69 fit
Triple-Branched Stent-Grafts
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Device Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Material Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Indication
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel30%
Digital / self-serve17%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Device Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Branched Aortic Stent-Graft System Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified46%
Sales qualified22%
Evaluation14%
Closed-won7%
$10.6KCAC
$61KLTV
5.8:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Branched Aortic Stent-Graft System Market is a high-growth opportunity — $10.4B by 2033, compounding at 11.3%.
TAM · 2025$4.39Btoday
TAM · 2033$10.4Bforecast
CAGR11.3%2027–2033
Cumulative$63.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$10.4BTotal addressable market
SAM$4.31BServiceable available market
SOM$899MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.3% CAGR
Demand compounds through 2033, outpacing GDP across Device Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Device Type moving from early to mainstream — durable secular demand.
Consolidation upside
13+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$10.4BLarge & growingTAM by 2033 at 11.3% CAGR
$4.31BServiceable nowreachable with today’s model
$899MBeachhead winobtainable near-term share
13+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$8.09BBear7.4% CAGR
$10.4BBase11.3% CAGR
$13.3BBull15.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Material Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Branched Aortic Stent-Graft System Market — a $6.81B market by 2033. Plan: grow share from 9.5% to 15.3%.
Market size · 2033$6.81Btotal addressable
Market CAGR4.9%2027–2033
Target share15.3%from 9.5% today
Revenue ambition$1.04Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.5% | 15.3% | At risk |
| Revenue | $676M | $1.04B | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 34.9% | 43.9% | Behind |
| Customer retention | 89.3% | 93.4% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Device Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Material Type capability
A defensible second engine — invest in Material Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Device Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Material Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $131M capacity & capability investment
- Greenlight bolt-on M&A in Material Type
- Authorise North America expansion plan
- Fund R&D program for Device Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeBehind
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Branched Aortic Stent-Graft System Market conversation — a $5.74B market you can size, segment and defend in minutes.
Market size · 2033$5.74Btotal opportunity
Growth9.0%CAGR to 2033
Addressable buyers1,172+accounts in scope
Typical ROI5.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Device Type
Goal Grow share in Device Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.4×return on cost, year one
< 3 mopayback period
$60K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
13+players profiled in this market
Coverage includes
MedtronicW.L. Gore & AssociatesCook MedicalTerumo CorporationEndologix (a subsidiary of Philips)Jotec GmbHBolton MedicalMicroPort Scientific Corporation+5 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Branched Aortic Stent-Graft System Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Branched Aortic Stent-Graft System Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Branched Chain Amino Acid 3H Injection Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportBranched Polyether Epoxy Resin Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportBranched Polyethylenimine (B-PEI) Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportBrand Activation Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportBrand and Design Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportBrand Clothing Label Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportBrand Fur Market
Market size, share, segmentation and regional forecast.
$806M market · 2025 base year
View reportBrand Protection Label Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportBranding Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportBrandy (Spirits) Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportBrandy Sales Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportBrannerite Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.